A phase I open label, non-randomized, dose-escalation, multi-center, therapeutic trial of the safety, immunogenicity and efficacy of GI-4000, an inactivated recombinant Saccharomyces cerevisiae immunotherapeutic expressing three different mutations of the Ras oncoprotein, in patients with solid tumors expressing mutations in Ras

Trial Profile

A phase I open label, non-randomized, dose-escalation, multi-center, therapeutic trial of the safety, immunogenicity and efficacy of GI-4000, an inactivated recombinant Saccharomyces cerevisiae immunotherapeutic expressing three different mutations of the Ras oncoprotein, in patients with solid tumors expressing mutations in Ras

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2005

At a glance

  • Drugs GI 4000 (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top